As of January 1, 2026, Jānis Buks, who has decided to focus on the development of his private business consulting company, will quit his job as the chairman of the board of AS “Olpha” pharmaceutical manufacturer, the LETA agency was informed by the company.
Accordingly, the “Olpha” council will continue its work as of January 1, consisting of five members.
Andrej Leibović, Aleksandr Livšić, Robert Taviev, Sergej Korniyenko and Vadim Telica are represented on the “Olpha” board. As of January 1, Leibovičs, who has been the vice-chairman of the council until now, will perform the duties of the chairman of the council.
The turnover of the “Olpha” (formerly “Olainfarm”) group was 126.874 million euros last year, which is 2.9% less than a year earlier, while the group’s profit decreased by 28% and reached 38.648 million euros, according to “Firmas.lv” information.
Meanwhile, Olpha itself worked with a turnover of 100.782 million euros last year, which is 10.6% less than in 2023, while the company’s profit fell by 41% to 30.636 million euros.
“Olpha” deals with finished dosage forms, pharmaceutical preparations and nutritional supplements, as well as with the production of chemicals and active pharmaceutical ingredients. “Olpha” was registered in 1991, and its share capital is currently EUR 3,000,004. The owner of the company is AS “AB City”, the parent company of AS “Repharm” group.
The real beneficiaries of “AB City”, according to the information published on the company’s website, are Sergej Korniyenko, Andrei Leibovich, Aleksandrs Livsits, Mihails Lurie, Yelena Nikitina and Roberts Tavievs.
Source: LETA
